BioTime Inc. (BTX)

2.33
0.02 0.87
AMEX : Health Technology
Prev Close 2.31
Open 2.32
Day Low/High 2.29 / 2.35
52 Wk Low/High 1.98 / 3.16
Volume 353.89K
Avg Volume 533.70K
Exchange AMEX
Shares Outstanding 126.88M
Market Cap 285.47M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioTime Subsidiary Asterias Biotherapeutics Reports The Successful End-of-Phase II FDA Meeting For Immunotherapy In Acute Myeloid Leukemia

BioTime Subsidiary Asterias Biotherapeutics Reports The Successful End-of-Phase II FDA Meeting For Immunotherapy In Acute Myeloid Leukemia

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics ("Asterias"), has successfully...

BioTime And Asterias Sign Share Transfer Agreement And Cross-License Agreement For Pluripotent Stem Cell Related Patents

BioTime And Asterias Sign Share Transfer Agreement And Cross-License Agreement For Pluripotent Stem Cell Related Patents

Asterias Biotherapeutics, Inc. (NYSE MKT:AST) and BioTime, Inc.

BioTime, Inc. To Present At Three Investor Conferences In February

BioTime, Inc. To Present At Three Investor Conferences In February

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, announced today that it will present at the following three investor conferences in February:...

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

BioTime, Inc. (NYSE MKT and TASE: BTX) announced today that pursuant to Section 6.

BioTime Completes Distribution Of Approximately 4.75 Million Shares Of OncoCyte Corporation Common Stock

BioTime Completes Distribution Of Approximately 4.75 Million Shares Of OncoCyte Corporation Common Stock

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, has completed its previously announced distribution of approximately 4.

BioTime Announces "When-Issued" Trading Of Subsidiary OncoCyte Corporation In Connection With Planned Distribution

BioTime Announces "When-Issued" Trading Of Subsidiary OncoCyte Corporation In Connection With Planned Distribution

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the common stock of its subsidiary OncoCyte Corporation ("OncoCyte") will...

OncoCyte Appoints Dr. Andrew J. Last To Its Board Of Directors

OncoCyte Appoints Dr. Andrew J. Last To Its Board Of Directors

OncoCyte Corporation ("OncoCyte"), a company focused on non-invasive cancer diagnostics, announced the appointment of Dr.

BioTime Co-Chief Executive Officer Michael D. West, PhD To Deliver Keynote Speech At The 2015 World Stem Cell Summit

BioTime Co-Chief Executive Officer Michael D. West, PhD To Deliver Keynote Speech At The 2015 World Stem Cell Summit

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its co-Chief Executive Officer Michael D.

BioTime, Inc. Announces Record Date, Distribution Ratio, And Distribution Date For Distribution Of Shares Of Subsidiary OncoCyte Corporation

BioTime, Inc. Announces Record Date, Distribution Ratio, And Distribution Date For Distribution Of Shares Of Subsidiary OncoCyte Corporation

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its Board of Directors has set the record date, the distribution...

BioTime, Inc. To Present At Oppenheimer Annual Healthcare Conference

BioTime, Inc. To Present At Oppenheimer Annual Healthcare Conference

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, is scheduled to present...

LifeMap Solutions Launches COPD Navigator App For Consumers And Commercial Partners

LifeMap Solutions Launches COPD Navigator App For Consumers And Commercial Partners

LifeMap Solutions, a digital-health subsidiary of BioTime, Inc. (NYSE MKT and TASE: BTX) known for its ResearchKit-enabled app Asthma Health, today announced that its HealthKit-compliant iOS app, COPD Navigator, is now...

BioTime, Inc. Announces The Appointment Of Life Sciences Industry Veteran Russell Skibsted As Chief Financial Officer

BioTime, Inc. Announces The Appointment Of Life Sciences Industry Veteran Russell Skibsted As Chief Financial Officer

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Company's Board of Directors has appointed Russell Skibsted...

Short Interest Jumps 11.8% For BTX

Short Interest Jumps 11.8% For BTX

The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, which shows a 826,152 share increase in total short interest for BioTime, Inc. , to 7,838,190, an increase of 11.78% since 10/15/2015.

Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders

Insider Trading Alert - TIPT, BTX And WASH Traded By Insiders

Stocks with insider trader activity include TIPT, BTX and WASH

BioTime, Inc. Reports Third Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Third Quarter 2015 Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE:BTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its recent accomplishments.

BioTime, Inc. And Hepregen Corporation Form Ascendance Biotechnology, Inc. To Address The In Vitro Cell Biology Market

BioTime, Inc. And Hepregen Corporation Form Ascendance Biotechnology, Inc. To Address The In Vitro Cell Biology Market

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company, and Hepregen Corporation, a privately held company engaged in the development and marketing of proprietary drug screening products,...

Adi Mohanty Joins Michael D. West, PhD, As Co-CEO Of BioTime, Inc.

Adi Mohanty Joins Michael D. West, PhD, As Co-CEO Of BioTime, Inc.

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, reported today that its Board of Directors has appointed Adi Mohanty to serve...

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement For Planned Distribution

BioTime's Subsidiary OncoCyte Corporation Files Form 10 Registration Statement For Planned Distribution

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary OncoCyte Corporation ("OncoCyte"), today announced that OncoCyte...

BioTime, Inc. Agrees To Sell $5.1 Million Of Equity

BioTime, Inc. Agrees To Sell $5.1 Million Of Equity

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it has agreed to sell 1,600,000 of its common shares, no par...

BioTime Announces The Closing Of A $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered

BioTime Announces The Closing Of A $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that BioTime completed a registered direct offering of 6,530,612...

Heraeus Medical GmbH And BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development And Licensing Agreements

Heraeus Medical GmbH And BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development And Licensing Agreements

Heraeus Medical GmbH, one of the leading companies in the field of bone cement and biomaterials for elective orthopedic and trauma surgery, and BioTime, Inc.

Mount Sinai And LifeMap Solutions Announce Initial Results For Asthma Health App And New Features To Enhance Clinical Impact

Mount Sinai And LifeMap Solutions Announce Initial Results For Asthma Health App And New Features To Enhance Clinical Impact

The Icahn School of Medicine at Mount Sinai and LifeMap Solutions, a digital-health subsidiary of BioTime, Inc.

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For OpRegen® for The Treatment Of The Dry Form Of Age-Related Macular Degeneration

BioTime's Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation For OpRegen® for The Treatment Of The Dry Form Of Age-Related Macular Degeneration

BioTime, Inc. (NYSE MKT and TASE: BTX) and its subsidiary Cell Cure Neurosciences Ltd.

BioTime, Inc. Agrees To Sell Up To $20.7 Million Of Common Shares

BioTime, Inc. Agrees To Sell Up To $20.7 Million Of Common Shares

BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.

BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond To Its Board Of Directors

BioTime Subsidiary OncoCyte Corporation Appoints Cavan Redmond To Its Board Of Directors

BioTime, Inc. (NYSE MKT and TASE: BTX) announced the appointment of Cavan Redmond as an independent member of the Board of Directors of BioTime's subsidiary OncoCyte Corporation.

BioTime, Inc. Agrees To Sell $8.58 Million Of Common Shares

BioTime, Inc. Agrees To Sell $8.58 Million Of Common Shares

BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell 2,607,401 of its common shares, no par value, at an offering price of $3.

BioTime Announces Dual Listing On The Tel Aviv Stock Exchange

BioTime Announces Dual Listing On The Tel Aviv Stock Exchange

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company focused on the development and commercialization of cell-based therapies, announced today that the Tel Aviv Stock Exchange (TASE) has approved the new listing of...

BioTime Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015

BioTime Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015

BioTime, Inc. (NYSE MKT:BTX) announced today that its Chief Executive Officer Michael D.

BioTime Management To Present At Rodman & Renshaw 17th Annual Global Investment Conference

BioTime Management To Present At Rodman & Renshaw 17th Annual Global Investment Conference

BioTime, Inc. (NYSE MKT:BTX) announced today that BioTime management will present at the Rodman & Renshaw 17th Annual Investment Conference in New York City from 3:00 to 3:25 p.

TheStreet Quant Rating: D (Sell)